News & Events

Today, Oncode Accelerator announced that ExpediteBio, a biotechnology company dedicated to accelerating the development, de-risking the progression, and enabling the early clinical validation of innovative antibody-based therapeutics, has joined its Biologics Workstream as a new partner. The collaboration strengthens Oncode Accelerator's ability to move promising anti-cancer antibody-based therapeutics from the lab bench towards first-in-human studies.Nederlandse versie

The Oncode Impact Foundation, a joint initiative of the Oncode Accelerator Foundation and Oncode Institute, launched today. It uses philanthropy to fund the development of new treatment options for cancer patients through the so-called ‘valley of death’: the crucial phase in which promising scientific breakthroughs often falter and fail to reach patients.

How cells communicate and develop is controlled by communication pathways. The so called Wnt signaling pathway plays a central role in almost all childhood liver tumors. Researchers from the Princess Máxima Center and Linköping University in Sweden - supported by Oncode Accelerator, Stichting Kinderen Kankervrij (KiKa) and the Princess Máxima Center Foundation (Kus van Kiki) - have now discovered how this pathway can result in tumor cells with different features within a single tumor. Their findings contribute to better classification of these tumors and, in the future, more tailored treatments.